Dr. Gargey Yagnik joins AmberGen as Program Coordinator for Mass Spectrometry. In his previous position as a postdoctoral researcher at Sanofi Genzyme he developed new methods for MALDI-MSI tissue imaging. He received his Ph.D. from Iowa State University in analytical chemistry.

AmberGen Founder and Chairman of the Board, Dr. Ken Rothschild, was elected as a Fellow of the National Academy of Inventors (NAI). The election as an NAI Fellow honors contributions from inventors who have made a tangible impact on quality of life, economic development and welfare of society.

John Gillespie, former Director of R&D for 3 Johnson & Johnson businesses including their multi-billion dollar Ethicon Products business, joins AmberGen as VP of Product and Business Development

AmberGen and Massachusetts General Hospital license the use of two novel autoantigen biomarkers for autoimmune liver disease to INOVA Diagnostics

http://www.marketwired.com/press-release/ambergen-mass-general-license-two-novel-autoantigen-biomarkers-autoimmune-liver-disease-1631270.htm

Agreement between AmberGen and SomaLogic® enables use of photocleavable reagent in SOMAmer® technology used to discover new biomarkers

AmberGen-SomaLogic Press Release

AmberGen wins Illumina’s VeraCode™ Assay Design Challenge for development of a multiplex colorectal cancer diagnostic

Promega distributes AmberGen’s fluorescent tRNA based protein engineering technology

https://www.promega.com/products/protein-expression/protein-labeling-and-detection/fluorotect-greenlys-in-vitro-translation-labeling-system/

Link Technologies Ltd. offers AmberGen’s Photocleavable Phosphoramidite DNA-labeling reagents in Europe

http://www.linktech.co.uk/products/modifiers/photocleavable_modifiers